Uniunea Europeană - engleză - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - clopidogrel (as hydrogen sulfate) - stroke; peripheral vascular diseases; myocardial infarction; acute coronary syndrome - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:- patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.- patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - docetaxel - stomach neoplasms; adenoma; breast neoplasms; carcinoma, non-small-cell lung; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancerdocetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinomadocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancerdocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloxetine - diabetic neuropathies - psychoanaleptics, - treatment of diabetic peripheral neuropathic pain in adults.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - epoetin delta - kidney failure, chronic; anemia - antianemic preparations - dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult patients. it may be used in patients on dialysis and in patients not on dialysis.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

pfizer limited - insulin human - diabetes mellitus - drugs used in diabetes - exubera is indicated for the treatment of adult patients with type 2 diabetes mellitus notadequately controlled with oral antidiabetic agents and requiring insulin therapy.exubera is also indicated for the treatment of adult patients with type 1 diabetes mellitus, inaddition to long or intermediate acting subcutaneous insulin, for whom the potential benefits ofadding inhaled insulin outweigh the potential safety concerns (see section 4.4).

Uniunea Europeană - engleză - EMA (European Medicines Agency)

unigene uk ltd. - recombinant salmon calcitonin - hypercalcemia; osteitis deformans; bone resorption - calcium homeostasis - calcitonin is indicated for:prevention of acute bone loss due to sudden immobilisation such as in patients with recentosteoporotic fracturespaget's diseasehypercalcaemia of malignancy

Uniunea Europeană - engleză - EMA (European Medicines Agency)

ecuphar - meloxicam - anti inflammatory and antirheumatic products - dogs; cats - oral suspension:dogs:alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.solution for injection:dogs:alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.cats:reduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

pfizer limited - e2 glycoprotein of classical swine fever virus - immunologicals for suidae - pigs - active immunisation of pigs, over the age of 2 weeks, against classical swine fever (csf), to preventmortality, reduce clinical signs of the disease and the excretion of field virus.the onset of protection is 2 weeks.the duration of protection is 6 months.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

sanofi pasteur s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

Uniunea Europeană - engleză - EMA (European Medicines Agency)

merial - inactivated ibr virus - immunologicals for bovidae - cattle - active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion., the onset of immunity is 14 days and the duration of immunity is 6 months.,